Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Why pregnant people were left behind while vaccines moved at ‘warp speed’ to help the masses

Kia Slade was seven months pregnant, unvaccinated, and fighting for breath, her oxygen levels plummeting, when her son came into the world last May.

24 Feb 2022

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

In a new study, researchers evaluated the efficacy and safety of nirmatrelvir in mild to moderate COVID-19 patients who were at high risk of severe COVID-19 disease.

18 Feb 2022

Trial of early antiviral therapy for COVID-19 shows no significant benefit

A new preprint research paper examines the efficacy of using three antivirals in various combinations in early infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Feb 2022

Risk factors for COVID-19 in older adult patients with cancer

Researchers develop a geriatric risk score to predict the risk of severe clinical outcomes in older cancer patients with COVID-19.

16 Feb 2022

UC joins nationwide trial to evaluate efficacy of repurposed drugs for mild-to-moderate COVID-19

The University of Cincinnati is joining a nationwide study to evaluate repurposed medications in the search for effective, safe treatments for mild-to-moderate COVID-19. Repurposed medications are those already approved by the U.S. Food and Drug Administration for other indications.

16 Feb 2022

Phase one study of oral SARS-CoV-2 antiviral agent nirmatrelvir

A recent study posted to the medRxiv* preprint server reported the phase one pharmacokinetic and safety data of nirmatrelvir/ritonavir to facilitate its rapid progression to the last stages of clinical trials in coronavirus disease 2019 (COVID-19) patients with mild to moderate disease.

14 Feb 2022

New research confirms the safety of mRNA COVID-19 vaccines for people with cancer

New research in the February 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms that mRNA vaccine for COVID-19 are just as safe for people with cancer as they are for cancer-free individuals.

10 Feb 2022

The new Omicron subvariant BA.2: what we know so far

Presently, an Omicron subvariant known as BA.2, first identified in late 2021, has made headlines due to its rapid spread.

26 Jan 2022

Neurological complications of the SARS-CoV-2 vaccine

In a study published in the latest issue of the journal Neurological Sciences, a team of researchers described a three-patient case series presenting with neurological manifestations after the coronavirus disease 2019 (COVID-19) vaccination, followed by a literature review, to propose hypotheses on how neurological symptoms might develop after vaccination.

24 Jan 2022

SARS-CoV-2 Omicron associated with fewer lower and more upper respiratory tract symptoms

Researchers assess the impact of the SARS-CoV-2 Omicron variant of concern on symptoms of SARS-CoV-2 infection.

23 Jan 2022

"Nocebo effect" accounts for 76% of all adverse events in the COVID-19 vaccine trial group

The placebo effect is the well-known phenomenon of a person's physical or mental health improving after taking a treatment with no pharmacological therapeutic benefit – a sugar pill, or a syringe full of saline, for example.

18 Jan 2022

What patients can learn with confidence from one negative rapid test (hint: very little)

Julie Ann Justo, an infectious disease clinical pharmacist for a South Carolina hospital system, hoped Christmas week would finally be the time her family could safely gather for a reunion.

13 Jan 2022

New combination immune therapy for cancer is effective and has fewer side effects, study finds

Google "chemotherapy side effects" and the results abound. Nausea, anemia, infection, fertility problems, kidney problems, mouth sores. The list goes on and on.

13 Jan 2022

Microbial characteristics of COVID-19

To better understand how the disease progresses, a recent paper in the journal Frontiers in Medicine discusses the role of the human microbiota in this condition.

13 Jan 2022

The Native Antigen Company Expands Range of Norovirus-Like Particles

The Native Antigen Company today announced the expansion of its norovirus-like particle range, with the addition of six new reagents.

From The Native Antigen Company 13 Jan 2022

Real-world effectiveness of three COVID-19 vaccines

Researchers from IQVIA Real-World Solutions have investigated how effective these vaccines are against severe disease.

11 Jan 2022

NCCN publishes new guidelines for managing patients with Graft-Versus-Host Disease

The National Comprehensive Cancer Network today announced the publication of new NCCN Guidelines for Patients: Graft-Versus-Host Disease (GVHD).

10 Jan 2022

Oral bacteria-based SARS-CoV-2 vaccine platform

In a new study, researchers engineered the bacterial strain, Salmonella, to express differently-sized antigens to serve as vaccine platforms.

5 Jan 2022

Both symptomatic and asymptomatic COVID-19 associated with increased risk of cardiovascular events

Researcers determine the risk of symptomatic and asymptomatic SARS-CoV-2 infection on post-acute cardiovascular events and all-cause mortality.

4 Jan 2022

New report on 1.23 million breakthrough symptomatic SARS-CoV-2 infections by vaccine

A new research letter evaluates whether the estimated vaccine effectiveness changes against infection over time.

28 Dec 2021

Nausea News and Research

Further Reading

Why pregnant people were left behind while vaccines moved at ‘warp speed’ to help the masses

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

Trial of early antiviral therapy for COVID-19 shows no significant benefit

Risk factors for COVID-19 in older adult patients with cancer

UC joins nationwide trial to evaluate efficacy of repurposed drugs for mild-to-moderate COVID-19

Phase one study of oral SARS-CoV-2 antiviral agent nirmatrelvir

New research confirms the safety of mRNA COVID-19 vaccines for people with cancer

The new Omicron subvariant BA.2: what we know so far

Neurological complications of the SARS-CoV-2 vaccine

SARS-CoV-2 Omicron associated with fewer lower and more upper respiratory tract symptoms

"Nocebo effect" accounts for 76% of all adverse events in the COVID-19 vaccine trial group

What patients can learn with confidence from one negative rapid test (hint: very little)

New combination immune therapy for cancer is effective and has fewer side effects, study finds

Microbial characteristics of COVID-19

The Native Antigen Company Expands Range of Norovirus-Like Particles

Real-world effectiveness of three COVID-19 vaccines

NCCN publishes new guidelines for managing patients with Graft-Versus-Host Disease

Oral bacteria-based SARS-CoV-2 vaccine platform

Both symptomatic and asymptomatic COVID-19 associated with increased risk of cardiovascular events

New report on 1.23 million breakthrough symptomatic SARS-CoV-2 infections by vaccine

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News